Lifestance Health Group ( (LFST) ) has provided an update.
LifeStance Health Group reported a 19% increase in revenue to $312.7 million for Q3 2024, driven by higher visit volumes and clinician growth. The company reduced its net loss to $6 million from $61.6 million last year and saw a 110% increase in Adjusted EBITDA to $30.7 million. With strong performance, LifeStance raised its full-year revenue outlook to $1.228-$1.248 billion, while maintaining positive free cash flow expectations. CEO Ken Burdick credited the team’s efforts in surpassing expectations and mitigating rate pressures.
Find detailed analytics on LFST stock on TipRanks’ Stock Analysis page.
